Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

23

Revenue 2017

Copaxone

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Copaxone was produced by Teva and Sanofi.

Teva wins FDA OK for crucial migraine drug

Teva wins FDA OK for crucial migraine drug

Copaxone (glatiramer acetate), its rapidly ageing cash-cow product. ... Ajovy is one of 23 New Drug Application (NDA) approvals Teva is targeting between fiscal 2019 and fiscal 2023 to help replace Copaxone and drive top-line growth, along with other

Dismay as NICE rejects Roche’s MS drug Ocrevus

Dismay as NICE rejects Roche’s MS drug Ocrevus At the same time It got the green light for RRMS, where there are multiple treatment options including beta interferons, Teva’s Copaxone (glatiramer acetate) and generics, and new oral therapies

Daily Brief: Azar blasts pharma, NICE forces MS drug prices down, Xenicos gets $30m funding

Daily Brief: Azar blasts pharma, NICE forces MS drug prices down, Xenicos gets $30m funding Teva’s Copaxone, Biogen’s Avonex and Merck Serono’s Rebif have all been accepted for routine use on the NHS after the companies agreed to lower their prices – in addition

Novartis doubles down on biosimilars with Biocon alliance

Novartis doubles down on biosimilars with Biocon alliance Previous launches have included its Glatopa version of Teva’s multiple sclerosis drug Copaxone (glatiramer acetate) and Zarxio, a variant of Amgen’s Neupogen (filgrastim).

Roche’s Ocrevus is first primary progressive MS drug in EU

Roche’s Ocrevus is first primary progressive MS drug in EU interferons and Teva’s Copaxone (glatiramer acetate), as well as new oral therapies such as Novartis’ Gilenya (fingolimod), have shown little benefit.

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt
...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again – in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics